Showing 1 - 10 of 237
Persistent link: https://www.econbiz.de/10013407493
Persistent link: https://www.econbiz.de/10002402037
As global e-waste streams rise, recycling efforts remain insufficient, as does the willingness to promote recycling. This insufficiency is primarily due to the perception of "waste" as "disposable", which has hindered its consideration as a business opportunity. Over time, this perception has...
Persistent link: https://www.econbiz.de/10014577690
With the ongoing trade normalisation process between India and Pakistan, opportunities to integrate have opened up between both countries. The pharmaceutical sector is crucial to health issues in developing economies and would be an ideal segment to focus on in improving trade relations between...
Persistent link: https://www.econbiz.de/10010404687
Persistent link: https://www.econbiz.de/10003344907
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals...
Persistent link: https://www.econbiz.de/10003900791
; Innovation ; Pharmaceuticals ; Health care expenditure ; Cointegration …
Persistent link: https://www.econbiz.de/10003900852
Many politicians blame physician dispensing (PD) to increase health care expenditure and to undermine independence of drug prescription and income leading to a suboptimal medication. Therefore, PD is not allowed in most OECD countries. In Switzerland, PD is allowed in some regions depending on...
Persistent link: https://www.econbiz.de/10003900934
Today, the global pharmaceutical product value chain is becoming increasingly complex and this has led to the emergence of 'multiple quality standards' for medicines. But this non-uniformity in the quality of medicine is also contingent upon both the regulatory milieu in the country of...
Persistent link: https://www.econbiz.de/10011337690
The German health care reform of 1997 provides a natural experiment for evaluating the price sensitivity of demand for physicians' services. As a part of the reform, co-payments for prescription drugs were increased step up to 200%. However, certain groups of people were exempted from the...
Persistent link: https://www.econbiz.de/10001806923